Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperbaric oxygen therapy for multiple sclerosis.

M Bennett1, R Heard

  • 1Diving and Hyperbaric Medicine, Prince of Wales Hospital, Barker St, Randwick, NSW, Australia.

The Cochrane Database of Systematic Reviews
|February 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperbaric oxygen therapy for acute coronary syndrome.

The Cochrane database of systematic reviews·2005
Same author

What does a good quality of life for cancer patients mean on a numerical rating scale?

Clinical oncology (Royal College of Radiologists (Great Britain))·2005
Same author

Hyperbaric oxygen for carbon monoxide poisoning.

The Cochrane database of systematic reviews·2005
Same author

Lambert-Eaton myasthenic syndrome associated with thymitis.

Neurology·2005
Same author

Systematic review of hyperbaric oxygen in the management of chronic wounds.

The British journal of surgery·2005
Same author

Intermittent and persistent shedding of Escherichia coli O157 in cohorts of naturally infected calves.

Journal of applied microbiology·2004
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Hyperbaric Oxygen Therapy (HBOT) shows no consistent evidence of benefit for Multiple Sclerosis (MS) treatment. Isolated findings of improvement require further investigation in well-designed trials before routine use is considered.

Area of Science:

  • Neurology
  • Oxygen Therapy
  • Clinical Trials

Background:

  • Multiple Sclerosis (MS) is a chronic, progressive neurological disease with no known cure.
  • Hyperbaric Oxygen Therapy (HBOT) has been speculatively proposed to potentially slow or reverse MS progression.

Purpose of the Study:

  • To systematically evaluate the efficacy and safety of Hyperbaric Oxygen Therapy (HBOT) as a treatment for Multiple Sclerosis (MS).

Main Methods:

  • Comprehensive literature search of multiple databases including Cochrane MS Group, Cochrane Central Register, MEDLINE, and NLM.
  • Inclusion of all randomized controlled trials comparing HBOT with sham therapy in MS patients.
  • Independent data extraction and methodological quality assessment by two reviewers.

Related Experiment Videos

Main Results:

  • Ten reports from nine trials (504 participants) met the selection criteria.
  • Two trials suggested positive results, while seven found no evidence of treatment effect.
  • A statistically significant improvement in the Expanded Disability Status Scale (EDSS) was observed in one analysis of the HBOT group (-0.85 points at 12 months).

Conclusions:

  • No consistent evidence supports the beneficial effect of HBOT for MS treatment.
  • The routine use of HBOT for MS is not currently justified.
  • Further well-designed trials are needed to confirm isolated suggestive findings, but are not warranted by this review.